HCC: Highlights from ILCA and ESMO 2021

December 06, 2023 00:13:19
HCC: Highlights from ILCA and ESMO 2021
COR2ED - Oncology Medical Conversation
HCC: Highlights from ILCA and ESMO 2021

Dec 06 2023 | 00:13:19

/

Show Notes

Professor Matthias Pinter, medical hepatologist from the medical University of Vienna in Austria shares some insights from key abstracts and topics discussed at ILCA 2021 and ESMO 2021 in hepatocellular carcinoma.

One main topic included discussions about treatment options in first-line systemic therapy and managing patients who still may need to receive a TKI in first-line instead. Another topic covered is how to proceed with immunotherapy in HCC, in particular the rationale for triplet immunotherapy combination.

There were two studies data presented on atezolizumab plus bevacizumab, the new reference standard of care in systemic front-line HCC treatment.

Another interesting topic was the combination of TACE with immune checkpoint blockade in intermediate stage HCC.

Regarding monotherapy TKI in first-line setting, Prof Pinter points out that around 15 to 20% of HCC patients are not ideal candidates for atezolizumab plus bevacizumab, and these are mainly patients with HCC recurrence of the liver transplantations, patients with severe autoimmune disease, or those with a high bleeding risk.

He discusses several real-world evidence studies including lenvatinib, sorafenib and regorafenib in special populations that are usually excluded from clinical trials.

 Prof Pinter also discusses data presented covering predictive and prognostic biomarkers such as cachexia, the growing role of AI, multibipolar radiofrequency ablation and the potential role of underlying etiology as a predictor of the efficacy of immunotherapy.

Other Episodes

Episode

December 06, 2023 00:32:39
Episode Cover

Neuroendocrine tumours: The role of SSA at progression - To continue or not?

In this podcast, Prof. Martyn Caplin and Dr Aman Chauhan discuss the role of somatostatin analogues (SSAs) at progression and whether to continue or...

Listen

Episode

December 06, 2023 00:18:01
Episode Cover

Precision oncology: Diagnosis and treatment of TRK fusion-positive GI cancers

In this podcast, PO CONNECT members Prof Frédérique Penault-Llorca (University of Clermont-Ferrand, France) and Prof Andrea Sartore-Bianchi (Niguarda Cancer Centre, Milan, Italy) provide both...

Listen

Episode

February 17, 2025 00:11:28
Episode Cover

Advanced or recurrent endometrial cancer: Molecular classification and treatment decisions

Advanced or recurrent endometrial cancer: Molecular classification and treatment decisions   Key clinical takeaways:   MMR status should be tested in all patients at diagnosis and...

Listen